Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stephen P Hunger

Showing results (191-200 of 346) with videos related to

Pageof 35
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 31, 2023
Children's Oncology Group AALL1331: Phase III Trial of Blinatumomab in Children, Adolescents, and Young Adults With Low-Risk B-Cell ALL in First RelapseLaura E Hogan, Patrick A Brown, Lingyun Ji, et al.
Pediatric Blood & Cancer|March 11, 2015
Safe integration of nelarabine into intensive chemotherapy in newly diagnosed T-cell acute lymphoblastic leukemia: Children's Oncology Group Study AALL0434Stuart S Winter, Kimberly P Dunsmore, Meenakshi Devidas, et al.
Leukemia|November 2, 2021
Outcomes in adolescent and young adult patients (16 to 30 years) compared to younger patients treated for high-risk B-lymphoblastic leukemia: report from Children's Oncology Group Study AALL0232Michael J Burke, Meenakshi Devidas, Zhiguo Chen, et al.
Nature Genetics|February 5, 2013
Relapse-specific mutations in NT5C2 in childhood acute lymphoblastic leukemiaJulia A Meyer, Jinhua Wang, Laura E Hogan, et al.
Leukemia|April 13, 2021
Correction to: FLT3 inhibitor lestaurtinib plus chemotherapy for newly diagnosed KMT2A-rearranged infant acute lymphoblastic leukemia: Children's Oncology Group trial AALL0631Patrick A Brown, John A Kairalla, Joanne M Hilden, et al.
Haematologica|December 15, 2018
Replacing cyclophosphamide/cytarabine/mercaptopurine with cyclophosphamide/etoposide during consolidation/delayed intensification does not improve outcome for pediatric B-cell acute lymphoblastic leukemia: a report from the COGMichael J Burke, Wanda L Salzer, Meenakshi Devidas, et al.
Haematologica|February 17, 2022
Outstanding outcomes in infants with <i>KMT2A</i>-germline acute lymphoblastic leukemia treated with chemotherapy alone: results of the Children's Oncology Group AALL0631 trialErin M Guest, John A Kairalla, Joanne M Hilden, et al.
Blood|May 13, 2011
Escalating intravenous methotrexate improves event-free survival in children with standard-risk acute lymphoblastic leukemia: a report from the Children's Oncology GroupYousif Matloub, Bruce C Bostrom, Stephen P Hunger, et al.
Pediatric Blood & Cancer|February 9, 2021
Prognostic impact of minimal residual disease at the end of consolidation in NCI standard-risk B-lymphoblastic leukemia: A report from the Children's Oncology GroupRachel E Rau, Yunfeng Dai, Meenakshi Devidas, et al.
Pediatric Blood & Cancer|August 17, 2023
Assessment of proxy-reported responses as predictors of motor and sensory peripheral neuropathy in children with B-lymphoblastic leukemiaRozalyn L Rodwin, Natalie J DelRocco, Emily Hibbitts, et al.
Pageof 35

Showing results (191-200 of 346) with videos related to

Sort By:
Pageof 35
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 31, 2023
Children's Oncology Group AALL1331: Phase III Trial of Blinatumomab in Children, Adolescents, and Young Adults With Low-Risk B-Cell ALL in First RelapseLaura E Hogan, Patrick A Brown, Lingyun Ji, et al.
Pediatric Blood & Cancer|March 11, 2015
Safe integration of nelarabine into intensive chemotherapy in newly diagnosed T-cell acute lymphoblastic leukemia: Children's Oncology Group Study AALL0434Stuart S Winter, Kimberly P Dunsmore, Meenakshi Devidas, et al.
Leukemia|November 2, 2021
Outcomes in adolescent and young adult patients (16 to 30 years) compared to younger patients treated for high-risk B-lymphoblastic leukemia: report from Children's Oncology Group Study AALL0232Michael J Burke, Meenakshi Devidas, Zhiguo Chen, et al.
Nature Genetics|February 5, 2013
Relapse-specific mutations in NT5C2 in childhood acute lymphoblastic leukemiaJulia A Meyer, Jinhua Wang, Laura E Hogan, et al.
Leukemia|April 13, 2021
Correction to: FLT3 inhibitor lestaurtinib plus chemotherapy for newly diagnosed KMT2A-rearranged infant acute lymphoblastic leukemia: Children's Oncology Group trial AALL0631Patrick A Brown, John A Kairalla, Joanne M Hilden, et al.
Haematologica|December 15, 2018
Replacing cyclophosphamide/cytarabine/mercaptopurine with cyclophosphamide/etoposide during consolidation/delayed intensification does not improve outcome for pediatric B-cell acute lymphoblastic leukemia: a report from the COGMichael J Burke, Wanda L Salzer, Meenakshi Devidas, et al.
Haematologica|February 17, 2022
Outstanding outcomes in infants with <i>KMT2A</i>-germline acute lymphoblastic leukemia treated with chemotherapy alone: results of the Children's Oncology Group AALL0631 trialErin M Guest, John A Kairalla, Joanne M Hilden, et al.
Blood|May 13, 2011
Escalating intravenous methotrexate improves event-free survival in children with standard-risk acute lymphoblastic leukemia: a report from the Children's Oncology GroupYousif Matloub, Bruce C Bostrom, Stephen P Hunger, et al.
Pediatric Blood & Cancer|February 9, 2021
Prognostic impact of minimal residual disease at the end of consolidation in NCI standard-risk B-lymphoblastic leukemia: A report from the Children's Oncology GroupRachel E Rau, Yunfeng Dai, Meenakshi Devidas, et al.
Pediatric Blood & Cancer|August 17, 2023
Assessment of proxy-reported responses as predictors of motor and sensory peripheral neuropathy in children with B-lymphoblastic leukemiaRozalyn L Rodwin, Natalie J DelRocco, Emily Hibbitts, et al.
Pageof 35